New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
Commentary|Articles|September 11, 2026
Rewriting the Playbook: How Biomarker-Driven Therapy Is Transforming Metastatic Prostate Cancer Care
Author(s)Manojkumar Bupathi, MD, MS, Jonah Feldman
Fact checked by: Sabrina Serani, Cheney Gazzam Baltz
For Prostate Cancer Awareness Month, Manojkumar Bupathi, MD, MS, examines how oncologists are changing practice after 4 key FDA approvals and a trend toward biomarker-driven therapy.
Advertisement
Advertisement
Prostate cancer treatment has entered one of its most active periods in years, with 4 vital new regimens gaining FDA approval in the metastatic hormone-sensitive prostate cancer (HSPC) setting within the past 12 months. That pace reflects a broader shift in the field: Treatment selection is increasingly guided by tumor and germline genetics, with therapies targeting BRCA mutations and PTEN deficiencies, as well as radioligand therapies being incorporated into existing androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (ARPI) combinations, rather than a one-size-fits-all approach to hormone-sensitive and hormone-resistant disease.
Related to this article
The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings.
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.
The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.
Advertisement
Advertisement